BioPharmaChem Ireland (BPCI), the Ibec group that represents the sector, today announced Dr. David Keenan, VP Global External Supply and Managing Director of Mallinckrodt Pharmaceutical Ireland, as it's new chairman. Dr. Keenan will serve a two year term and replaces outgoing Chair Seamus Fives, Site Leader at Pfizer Pharmaceuticals.
Commenting on the new appointment during BCPI's AGM in Dublin today, Director of BPCI Matt Moran stated: "I would personally like to thank Seamus Fives for his long standing contribution to the work of BPCI to date and for his support throughout his term of office. We work in an exciting, dynamic and innovative industry that is a key driver of the substance behind the Irish business model, and I look forward to continuing this momentum with our incoming Chair Dr. David Keenan whom I know will strive to further the growth prospects for our sector in the years ahead.
"The biopharmaceutical sector has been a major driver of business substance and export growth, with the latest figures at €55 billion accounting for 58% of Irish goods exports. With investment of more than €4 billion in the past couple of years, we're now preparing for a rapid and substantial increase in job creation with as many as 8,400 jobs to be added by 2020."
Addressing discussions on Dublin’s bid to house the European Medicines Agency (EMA) during the AGM Mr Moran stated: “Ireland has a very strong global life sciences base and is home to many of the world leading biopharmaceutical companies. We have a proven track record in world class collaboration between industry, research and regulation. Dublin is therefore the natural choice to host the European Medicines Agency. BPCI strongly supports the Government campaign to secure this prestigious agency for Ireland. It is our belief that the presence of the EMA in Ireland will help to drive further the diversification of the sector in Ireland."